Are Research Fees Received by a Doctor Exempt from GST?

Healthcare exemption, clinical research, pharmaceutical engagements and registration consequences

Short answer  No.

A doctor does not receive a blanket GST exemption merely because the supplier is a doctor. The exemption follows the service. Patient-specific diagnosis, treatment or care is generally exempt. A research paper, literature review, protocol design, clinical-trial data generation, scientific consultancy or contract research deliverable is ordinarily taxable, usually at 18%.

That is the first, and most important, question. The answer is no.

GST law does not exempt a person merely because he or she holds an MBBS, MD or other recognised medical qualification. Entry 74 of Notification No. 12/2017-Central Tax (Rate), dated 28 June 2017, exempts a defined category of services. Therefore, the correct enquiry is not ‘Who raised the invoice?’ but ‘What was supplied under the contract?’

A doctor may make several supplies in the same financial year. Consultation, diagnosis, surgery and patient care may be exempt. A paid medical research report, advisory assignment, product study, protocol review, speaking engagement, brand endorsement or business-development assignment may be taxable. Each stream must be classified on its own substance.

The exemption entry and its boundaries

Entry 74 of Notification No. 12/2017

Entry 74 under Heading 9993 grants a nil rate to services by way of:

• healthcare services supplied by a clinical establishment, an authorised medical practitioner or para-medics; and

• transportation of a patient in an ambulance, other than transportation already covered by the first limb.

For an individual doctor, the relevant limb is healthcare services supplied by an authorised medical practitioner. The expression ‘authorised medical practitioner’ broadly refers to a practitioner registered with a council of a recognised system of medicine, including a qualified professional entitled by law to practise such a system.

What counts as ‘healthcare services’?

Paragraph 2(zg) of the notification defines healthcare services as a service by way of diagnosis, treatment or care for illness, injury, deformity, abnormality or pregnancy in a recognised system of medicines in India. It includes transport of a patient to and from a clinical establishment. It excludes hair transplant and cosmetic or plastic surgery, except where undertaken to restore or reconstruct anatomy or bodily functions affected by congenital defects, developmental abnormalities, injury or trauma.

The statutory test  There must be a sufficiently direct link with the diagnosis, treatment or care of a patient. Medical subject matter alone is not enough. Research about an illness is not automatically care of a person suffering from that illness.

CBIC Circular No. 32/06/2018-GST, dated 12 February 2018, clarifies that services of senior doctors, consultants and technicians hired by a hospital, whether as employees or otherwise, are exempt healthcare services when the payment is for healthcare supplied to patients. The Karnataka High Court in HealthCare Global Enterprises Ltd. v. Commercial Tax Officer (30 April 2026) relied upon this circular while recognising the healthcare character of services rendered by doctors and consultants engaged by hospitals.

The circular does not say that every cheque issued by a hospital to a doctor is exempt. The hospital’s status does not convert an independent research deliverable into treatment. The engagement letter, patient linkage, responsibility assumed, deliverables, invoicing description and commercial object remain decisive.

Research services under GST

Classification must follow the actual scope. A literature review or expert opinion may fall under professional or technical services rather than experimental R&D. The rate is commonly still 18%, but the correct SAC should be chosen from the agreement and deliverables, not from a generic invoice label.

Scenario 1: Research fees paid by a hospital

The same hospital can purchase both exempt healthcare and taxable research from the same doctor. The following distinction is practical:

Where a pharmaceutical or biotechnology company, sponsor or contract research organisation pays the doctor to generate evidence about a drug, device, protocol or disease area, the commercial recipient ordinarily buys research, testing, scientific advice or trial services. Such consideration is not exempt merely because patients are examined or because the investigator is a doctor.

Typical taxable deliverables include protocol feasibility, investigator services, patient recruitment for a study, informed-consent administration, trial visits undertaken under protocol, case-report forms, source-data verification support, safety reporting, sample collection for study endpoints, medical monitoring, literature reviews, publication support, investigator meetings, advisory-board participation and final research reports.

A narrow patient-care component may still be exempt where it is independently contracted and genuinely supplied as diagnosis or treatment to the patient or hospital. However, artificial splitting is risky. If the services form one naturally bundled supply whose principal objective is research, the bundle will ordinarily follow the research service. Conversely, routine inpatient treatment does not become taxable merely because the patient’s clinical data later informs an observational study, provided the contracted supply and consideration are truly for treatment.

Does the doctor need GST registration?

Sections 22 and 23 of the CGST Act must be read together with the definition of aggregate turnover in section 2(6). For a service provider, the normal threshold is Rs.20 lakh in a financial year, or Rs.10 lakh in the notified special-category States. The Rs.40 lakh threshold is for persons engaged exclusively in supply of goods and is not the general threshold for doctors supplying services.

Aggregate turnover is PAN-India and includes taxable supplies, exempt supplies, exports and inter-State supplies of persons having the same PAN, while excluding GST itself and inward supplies taxed under reverse charge. Consequently, exempt consultation and hospital receipts count for testing the registration threshold.

div style="clear:both;">After becoming registered, the doctor should issue a tax invoice and charge CGST plus SGST for an intra-State taxable assignment or IGST for an inter-State taxable assignment. Research services supplied by an individual doctor to a hospital or pharmaceutical company are not generally covered by a special reverse-charge entry; the ordinary position is forward charge by the doctor. Exempt healthcare should continue to be reported separately as exempt turnover.

How the healthcare and life-sciences industry usually structures these payments

Clinical research commonly involves several parties, each performing a different legal and commercial role:

• The sponsor, usually a pharmaceutical, biotechnology or medical-device company, owns or commissions the study and funds it.

• A CRO may design, coordinate, monitor and document the trial for the sponsor.

• The hospital or research site provides infrastructure, pharmacy, laboratory, records and site administration.

• The principal investigator and sub-investigators perform protocol duties, protect participants, assess eligibility and safety, and generate study records.

• Patients or trial participants receive protocol-related procedures and may also receive ordinary clinical care.

Industry agreements often separate investigator fees, site-management charges, institutional overhead, ethics-committee fees, diagnostic tests, patient travel reimbursement, study drugs and ordinary standard-of-care treatment. That separation is valuable for GST only when it reflects economic reality. A single undifferentiated description such as ‘professional fees’ or ‘medical fees’ creates avoidable classification risk.

Practical drafting and invoicing checklist

• Identify the recipient and commercial purpose. Is the hospital buying patient care, or is a sponsor/CRO buying evidence, analysis or study performance?

• Describe deliverables precisely. Separate consultation/treatment from protocol, research, data, publication and project-management obligations.

• Use the correct SAC.

• Maintain separate values and invoices where exempt healthcare and taxable research are genuinely distinct. Avoid an artificial split of one composite research contract.

• Monitor aggregate turnover across the PAN, including exempt healthcare receipts. Do not monitor only taxable research fees.

• Register before issuing taxable invoices once liability arises, charge tax under forward charge, report exempt turnover separately and apply proportionate input-tax-credit restrictions under section 17 where common inputs serve both exempt and taxable supplies.

• For overseas contracts, separately document recipient location, payment, place of supply, whether the doctor acts on own account, and all export-of-services conditions.

• Retain the contract, protocol, ethics approval, invoices, patient-care records, deliverables and correspondence. GST character will be tested from substance, not the invoice caption alone.

Conclusion

The phrase ‘research fees received by a doctor’ cannot be answered by looking at the doctor’s qualification or the payer’s identity alone. Entry 74 protects healthcare, meaning diagnosis, treatment or care of a patient by the specified providers. It does not create a profession-wide exemption.

Accordingly, a hospital’s payment to a visiting consultant for treating its patients is generally exempt. A hospital’s payment for a research report, or a pharmaceutical company’s payment for clinical-trial performance, protocol work, data generation, literature review or scientific consultancy, is ordinarily taxable at 18%, under the appropriate research or professional-services classification. Where the doctor already has exempt healthcare turnover above the registration threshold, the commencement of any taxable research stream can trigger registration because exempt receipts are part of aggregate turnover.

The safest approach is to classify each agreement before the first invoice, separate true patient care from research deliverables, and align the GST treatment with the contract, regulatory approvals and actual conduct.

Disclaimer : This article is for informational purposes only and should not be construed as legal or professional advice. Taxpayers should consult their tax advisor based on the facts of their specific case before taking any action.